Dan Rosenbaum

Chief Executive Officer at

Kaydence Pharma USA

Health Technology

Consumer Services

Process Industries

Profile

Daniel Harris Rosenbaum is currently the Chief Executive Officer at Kaydence Pharma USA. Prior to this, he was the Chief Executive Officer at NattoPharma ASA from 2015 to 2018.
He also worked as the General Manager-Nutraceuticals & Pharmaceutical at FMC Corp.
Mr. Rosenbaum completed his undergraduate degree at Cornell University and earned an MBA from Tuck School of Business at Dartmouth.

Dan Rosenbaum active positions

Companies	Position	Start
Kaydence Pharma USA Kaydence Pharma USA Pharmaceuticals: MajorHealth Technology Develops menaquinone-7 for the treatment of vascular and tissue calcification-related diseases	Chief Executive Officer	-

All active positions of Dan Rosenbaum

Former positions of Dan Rosenbaum

Companies	Position	End
NATTOPHARMA ASA	Chief Executive Officer	10/02/2018
FMC CORPORATION	Corporate Officer/Principal	-

See the detail of Dan Rosenbaum's experience

Training of Dan Rosenbaum

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Dan Rosenbaum's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	5
FMC Corp. FMC Corp. Chemicals: AgriculturalProcess Industries Operates as an agricultural sciences company which produces insecticides, herbicides and fungicides & crop nutrition and seed treatment products	Process Industries
Cornell University Cornell University Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
NattoPharma ASA NattoPharma ASA Pharmaceuticals: MajorHealth Technology Manufactures, distributes, markets and sells vitamin K2 products	Health Technology
Tuck School of Business at Dartmouth Tuck School of Business at Dartmouth Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Kaydence Pharma USA Kaydence Pharma USA Pharmaceuticals: MajorHealth Technology Develops menaquinone-7 for the treatment of vascular and tissue calcification-related diseases	Health Technology